Background
==========

The importance of non glucose carbohydrates for normal fetal and neonatal development is becoming increasingly recognized, especially for mannose and inositol \[[@B1]-[@B4]\]. Carbohydrates not only serve as substrates for the glycolytic pathway, but also are critical for glycoprotein formation \[[@B5]\], phospholipid and glycerol production \[[@B2],[@B6]\], and neural development \[[@B7],[@B8]\]. Insights into fetal metabolism of mannose and inositol have been provided by recent reports which show that, like glucose, the fetus is dependent on its mannose supply from the mother. Conversely, the fetus and placenta endogenously produce inositol from glucose \[[@B9],[@B10]\]. In the term neonate, the utilization rates of mannose and inositol are much higher than the rate which could be obtained from human milk, suggesting endogenous production of both substrates after birth to meet daily requirements \[[@B11],[@B12]\].

Pathological conditions in pregnancy such maternal under nutrition, placental insufficiency, and diabetes have the potential to increase or decrease the delivery of carbohydrates to the fetus and adversely affect growth, body composition, and long term outcomes in human and livestock pregnancy \[[@B13],[@B14]\]. For example, diabetic pregnancies are characterized by increased glucose transfer to the fetus with subsequent elevations in fetal insulin concentrations \[[@B15]\]. In adults, insulin regulates mannose concentrations independent of glucose by suppression of hepatic mannose production \[[@B16]-[@B19]\]. Thus, the fetus is potentially at risk for hypomannosemia, both from fetal hyperinsulinemia as well as from decreased mannose delivery from the mother if insulin is used to manage maternal diabetes. Placental insufficiency in humans and sheep, on the other hand, restricts glucose delivery to the fetus leading to decreased fetal glucose and insulin concentrations \[[@B20],[@B21]\]. Placental insufficiency in pregnant sheep also decreases fetal sorbitol and inositol concentrations \[[@B22]\]. Thus, a better understanding of the metabolism of non glucose carbohydrates during pregnancy is warranted, especially when carbohydrate supply to the fetus is compromised.

We experimentally decreased maternal glucose concentrations in sheep pregnancies using an insulin infusion both short term (2-wk) and long term (8-wk) to test the hypothesis that a maternal insulin infusion would suppress maternal and thus fetal mannose and inositol concentrations. We also used direct fetal insulin infusions in the form of a 1-wk hyperinsulinemic-isoglycemic clamp to determine the relative importance of fetal glucose and insulin concentrations for regulating fetal non glucose carbohydrates. Finally, we report for the first time the concentrations of several other carbohydrates and polyols under each of these conditions.

Methods
=======

Surgical preparation
--------------------

Three separate groups of Columbia-Rambouillet ewes with singleton pregnancies were used for the following experiments: 1) 2-wk maternal insulin infusion, 2) 8-wk maternal insulin infusion, and 3) 1-wk direct fetal insulin infusion. All maternal and fetal surgical preparations and post operative care have been previously described \[[@B23]-[@B25]\]. Maternal femoral venous and arterial catheters were placed through a left groin incision. Fetal infusion catheters were placed into fetal femoral veins via hind limb pedal veins and sampling catheters were placed into the fetal abdominal aorta via a hind limb pedal artery. Ewes were fed Premium Alfalfa Pellets (Standlee; Kimberly ID) and intake was not different between control and hypoglycemic groups (1.80 ± 0.10 kg/d control; 1.59 ± 0.10 kg/d hypoglycemic).

Care and use of animals
-----------------------

All animal procedures have followed established standards for the humane care and use of animals and were in compliance with guidelines of the United States Department of Agriculture, the National Institutes of Health, and the American Association for the Accreditation of Laboratory Animal Care. The animal care and use protocols were approved by the University of Colorado Institutional Animal Care and Use Committee.

Experimental design
-------------------

### Two-Wk maternal insulin infusion

For the 2-wk maternal insulin infusion group and their respective controls, maternal and fetal catheters were surgically placed at 122.8 ± 1.3 d of gestation (dGA; term = 148 dGA) \[[@B23],[@B26]-[@B28]\]. One randomly assigned group received a continuous maternal infusion of intravenous insulin for 2-wk. Maternal arterial plasma glucose was measured at least twice daily and the insulin infusion was adjusted to achieve a 40-50% reduction in glucose concentrations (2-wk HG; n = 8). Maternal insulin concentrations are approximately doubled by this experimental design \[[@B29]\]. The control group received a maternal saline infusion at rates matched to the insulin infusion rates (2-wk C; n = 13). Fetal arterial plasma was sampled at the end of the 2-wk maternal infusion period for insulin and carbohydrate measurements.

### Eight-Wk maternal insulin infusion

For the 8-wk maternal insulin group and their respective controls, an initial surgery was performed at 70.0 ± 0.8 dGA to place maternal catheters \[[@B25]\]. One randomly assigned group (n = 9) received a continuous maternal infusion of intravenous insulin for 8-wk. Maternal arterial plasma glucose was measured at least twice daily and the insulin infusion was adjusted to achieve a 40-50% reduction in glucose concentrations. Maternal insulin concentrations are approximately doubled by this experimental design \[[@B30],[@B31]\]. The control group received a maternal saline infusion at rates matched to the insulin infusion rates (8-wk C; n = 5). At 119.4 ± 0.5 dGA, a second surgery was performed to place fetal catheters. After the second surgery, 8-wk HG ewes were further randomly divided into 2 groups. Fetuses in one of these groups received a direct fetal insulin infusion for the final week of the study (8-wk HG+I; n = 4). The insulin infusion was kept constant at 100 mU/h (using necropsy weights = 38.9 mU/kg/h ± 2.8) and ran concurrently with a direct fetal infusion of 33% dextrose (wt/vol) to prevent a further fall in fetal glucose concentrations. Fetal arterial plasma glucose concentrations were measured at least twice daily and the dextrose infusion was adjusted accordingly. The other group received a direct fetal saline infusion matched at equal infusion rates to the combined insulin and dextrose infusion (8-wk HG; n = 5). Finally, fetuses in the 8-wk C group also received a direct fetal saline infusion at equal rates. Fetal arterial plasma was sampled at the end of the infusions for insulin and carbohydrate measurements.

### One-Wk fetal insulin infusion

Six late gestation animals were used in this experiment. Fetal catheters were placed at 118.5 ± 0.6 dGA. All fetuses received an insulin infusion with a concurrent dextrose infusion into a fetal hind limb vein. The insulin infusion rate was progressively increased such that infusion rates ranged from 36.6 ± 8.4 mU/h on the first day to 121.8 ± 1.2 mU/h on the final d. The fetal dextrose infusion was adjusted to prevent a fall in glucose concentrations based on measurement of fetal arterial plasma glucose once or twice daily. Baseline, 4d, and 7d fetal arterial plasma was sampled for insulin and carbohydrate measurements.

Biochemical analysis
--------------------

Whole blood was collected in EDTA-coated syringes and immediately centrifuged (14,000 g) for 3 min at 4°C. Plasma was removed and the glucose concentration immediately determined using the YSI model 2700 select biochemistry analyzer (Yellow Springs Instruments, Yellow Springs, OH) \[[@B23]\]. The remainder of the plasma was stored at −70°C for insulin and carbohydrate measurements. Insulin (Alpco; inter-assay and intra-assay coefficients of variation: 2.9 and 5.6%) was measured by enzyme-linked immunosorbent assay \[[@B23]\]. Plasma was analyzed for mannose, inositol, fructose, mannitol, erythritol, arabinol, sorbitol and ribitol by HPLC as we have previously described \[[@B9]\].

Postmortem exam
---------------

Liver tissue from the right hepatic lobe was obtained in the 8-wk HG, 8-wk C, and 8-wk HG+I fetuses under conditions closely approximating *in vivo* study conditions as previously described for measurement of sorbitol and fructose \[[@B25]\].

Statistical analysis
--------------------

Statistical analysis was performed with SAS v.9.2 (SAS Institute) and GraphPad Prism 4. Results are expressed as mean ± SEM. *P*-values less than 0.05 were considered significant. The 2-wk HG and C fetuses were compared with Student's *t* test (parametric data) or the Mann--Whitney test (non parametric data). The 8-wk HG, HG+I, and C fetuses were compared with a one-way ANOVA. For measurements taken at multiple time points within an animal a mixed models ANOVA was used with terms for experimental group, time, group by time interaction as indicated. Repeated measurements made within an animal were accounted for. Post-test comparisons were made using Fishers least squares difference if the overall ANOVA had a *P* \< 0.05.

Results
=======

Two-Wk maternal insulin infusion
--------------------------------

### Fetal insulin, carbohydrates, and polyols

As previously reported \[[@B23],[@B26]-[@B28]\], gestational ages were similar, but fetal weight, fetal arterial plasma insulin, and glucose were 24%, 63%, and 49% lower, respectively in the 2 wk HG group (*P* \< 0.01, Table [1](#T1){ref-type="table"}). We found lower fetal arterial plasma concentrations of mannose (35%, *P* \< 0.01), sorbitol (57%, *P* \< 0.01), and fructose (60%, *P* \< 0.01) in the 2-wk HG group (Table [1](#T1){ref-type="table"}). Although the mean arterial plasma inositol concentration was nearly doubled in the 2-wk HG fetuses this did not reach statistical significance. Other fetal plasma carbohydrate concentrations were similar between 2-wk HG and C groups (Table [1](#T1){ref-type="table"}).

###### 

Two-Wk maternal insulin infusion

  **Measurement**                                 **Control**    **Hypoglycemic**
  --------------------------------------------- --------------- ------------------
  Gestational age, d                              138.5 ± 0.4      137.5 ± 0.8
  Fetal weight, kg                                4.37 ± 0.14    3.30 ± 0.18\*\*
  Fetal plasma arterial insulin, ng/mL            0.30 ± 0.03    0.11 ± 0.01\*\*
  Fetal plasma arterial carbohydrates, μmol/L                   
   Glucose                                        1,159 ± 64       594 ± 47\*\*
   Mannose                                        24.5 ± 1.2      15.9 ± 1.4\*\*
   Inositol                                      638.5 ± 138.6   1,129.0 ± 256.1
   Sorbitol                                      123.8 ± 12.7    53.9 ± 10.5\*\*
   Fructose                                       4771 ± 450     1,909 ± 356\*\*
   Erythritol                                    399.6 ± 28.1      345.9 ± 20.8
   Arabinol                                      245.0 ± 11.9      225.3 ± 15.6
   Ribitol                                        128.1 ± 9.1      148.5 ± 18.8
   Mannitol                                       72.8 ± 9.7       49.8 ± 10.1

Values are means ± SEM. \*\* refer to significant differences between Control (n = 13) and Hypoglycemic (n = 8); *P* \< 0.01 by Students *t* test or the Mann--Whitney test.

Eight-Wk maternal insulin infusion
----------------------------------

### Maternal plasma carbohydrates and polyols

Since 2-wk maternal insulin infusion experiments focused only on plasma carbohydrate changes in the fetal circulation, we included maternal carbohydrate analysis with the 8-wk insulin infusion studies. Consistent with study design, maternal arterial plasma glucose concentrations in the 8-wk HG group were approximately 40% lower compared to 8-wk C group throughout the insulin infusion period as previously reported (Table [2](#T2){ref-type="table"}, *P* \< 0.01) \[[@B25]\]. Maternal arterial plasma mannose concentrations also were 48% lower in the 8 wk HG group (Table [2](#T2){ref-type="table"}, *P* \< 0.01), but maternal arterial plasma inositol, sorbitol, erythritol, arabinol, and ribitol did not change (Table [2](#T2){ref-type="table"}).

###### 

Eight-Wk maternal insulin infusion

  **Measurement**                                    **Control**    **Hypoglycemic**       **HG+I**
  ------------------------------------------------ --------------- ------------------ ------------------
  Gestational age, d                                 133.2 ± 1.1      133.0 ± 1.3        134.5 ± 0.9
  Maternal plasma arterial carbohydrates, μmol/L                                      
   Glucose                                           3,605 ± 203    1,715 ± 145\*\*     1,817 ± 95\*\*
   Mannose                                           67.0 ± 4.3      34.7 ± 3.5\*\*     31.4 ± 5.0\*\*
   Inositol                                          27.7 ± 4.4        34.9 ± 3.9         34.6 ± 3.1
   Sorbitol                                          13.4 ± 3.4        18.8 ± 4.2         11.8 ± 1.3
   Erythritol                                        52.8 ± 5.5        44.5 ± 3.1         39.6 ± 8.5
   Arabinol                                          96.2 ± 13.3      125.6 ± 6.5        118.0 ± 23.3
   Ribitol                                           25.6 ± 3.0        25.9 ± 3.2         16.1 ± 4.3
  Fetal weight, kg                                   3.66 ± 0.12    2.20 ± 0.14\*\*    2.61 ± 0.21\*\*
  Fetal plasma arterial insulin, ng/mL               0.46 ± 0.09     0.16 ± 0.03\*       0.66 ± 0.17
  Fetal plasma arterial carbohydrates, μmol/L                                         
   Glucose                                           1,553 ± 282      587 ± 56\*\*       511 ± 37\*\*
   Mannose                                           30.4 ± 3.8      17.0 ± 1.1\*\*     7.9 ± 0.9\*\*
   Inositol                                         741.4 ± 240.8    910.1 ± 157.5      792.2 ± 199.5
   Sorbitol                                         188.5 ± 31.9    55.2 ± 11.9\*\*     41.3 ± 8.3\*\*
   Fructose                                          4,508 ± 981    1,631 ± 301\*\*     800 ± 154\*\*
   Erythritol                                       394.6 ± 30.7      372.2 ± 9.3        311.6 ± 24.6
   Arabinol                                         235.3 ± 17.1      237.5 ± 15.1       214.9 ± 54.3
   Ribitol                                          124.3 ± 15.9      139.6 ± 21.7       156.8 ± 57.6
   Mannitol                                          47.4 ± 8.5        31.4 ± 6.1         33.8 ± 8.7
  Fetal hepatic sorbitol and fructose, nmol/g                                         
   Sorbitol                                         589.0 ± 90.1    205.8 ± 42.1\*\*   161.3 ± 56.0\*\*
   Fructose                                          1,679 ± 219     398 ± 119\*\*       215 ± 95\*\*

Values are means ± SEM. \*, \*\* refer to significant differences from Control (n = 5) animals; *P* \< 0.05, 0.01, respectively, by ANOVA.

### Fetal insulin, carbohydrates, and polyols

As previously reported, gestational age at the time of study was not different between the groups. Fetal weights were 40% lower in the 8-wk HG group compared to 8-wk C (Table [2](#T2){ref-type="table"}, *P* \< 0.01) \[[@B25]\]. Fetal arterial plasma insulin and glucose were lower in the 8-wk HG group (*P* \< 0.05, Table [2](#T2){ref-type="table"}) \[[@B25]\]. Fetal arterial plasma mannose was 44% lower (*P* \< 0.01), as were sorbitol (71%, *P* \< 0.01) and fructose (64%, *P* \< 0.01, Table [2](#T2){ref-type="table"}). Furthermore, the arterial plasma maternal - fetal mannose difference also was lower (*P* \< 0.01, Figure [1](#F1){ref-type="fig"}A), and fetal and maternal arterial plasma mannose concentrations were highly correlated (Figure [1](#F1){ref-type="fig"}B). Fetal arterial plasma inositol, erythritol, arabinol, ribitol, and mannitol were similar between 8-wk HG and C groups (Table [2](#T2){ref-type="table"}).

![**Fetal and maternal mannose concentrations following an eight wk maternal insulin infusion. A)** The maternal-fetal arterial plasma mannose difference measured in control (n = 5), hypoglycemic (n = 5), and hypoglycemic + insulin (HG + I, n = 4).\* indicates *P* \< 0.05. Values are mean ± SEM. **B)** In both control (black squares, n = 5) and hypoglycemic fetal sheep (open circles, n = 5) fetal and maternal arterial plasma mannose concentrations are highly correlated in control (black squares) hypoglycemic animals (r^2^ = 0.69, *P* \< 0.01).](2049-1891-5-28-1){#F1}

A direct fetal insulin infusion for the final wk of the 8-wk maternal insulin infusion with a concurrent direct fetal dextrose infusion to prevent a further fall in fetal arterial plasma glucose was used to determine the effect of fetal glucose and insulin concentrations on regulating fetal non glucose carbohydrates. The direct fetal insulin infusion with a concurrent dextrose infusion (HG+I) resulted in fetal arterial plasma insulin concentrations 3-fold higher than HG fetuses (*P* \< 0.05) without a change in fetal arterial plasma glucose concentrations (Table [2](#T2){ref-type="table"}), as previously reported \[[@B25]\]. HG+I fetuses demonstrated even lower arterial plasma mannose concentrations when compared to the HG group (53%, *P* \< 0.05), and had mean fructose concentrations which were over 50% lower, though this failed to reach statistical significance (*P* = 0.058 by post hoc Student's *t* test). There was no effect on fetal arterial plasma inositol, sorbitol, erythritol, arabinol, ribitol, and mannitol (Table [2](#T2){ref-type="table"}). Fetal hepatic sorbitol and fructose concentrations were lower in the 8-wk HG group compared to C fetal livers (*P* \< 0.01, Table [2](#T2){ref-type="table"}). HG+I fetuses did not have changes in hepatic sorbitol or fructose compared to the 8-wk HG fetuses (Table [2](#T2){ref-type="table"}).

One-Wk fetal insulin infusion
-----------------------------

In order to determine the effect of fetal glucose and insulin concentrations for regulating non glucose carbohydrates in fetuses whose mothers did not receive a chronic insulin infusion, we infused 6 fetuses directly with insulin with a concurrent dextrose infusion to maintain fetal glucose concentrations for 1 wk beginning on 125.2 ± 0.7 dGA. Fetal plasma arterial glucose concentrations were stable throughout the infusion period, however the dextrose infusion was increased progressively during the insulin infusion period to maintain euglycemia, starting at 3.6 ± 1.1 mg/min and ending at 12.1 ± 2.5 mg/min. Fetal arterial plasma insulin, carbohydrate, and polyol concentrations were measured at baseline and on d 4 and d 7 of the insulin infusion (Table [3](#T3){ref-type="table"}). Fetal arterial plasma insulin concentrations were increased (*P* \< 0.01) and fetal arterial plasma mannose, fructose, and erythritol concentrations were decreased (*P* \< 0.05).

###### 

One-Wk fetal insulin infusion

  **Measurement**                                   **d0**           **d4**             **d7**
  --------------------------------------------- --------------- ----------------- ------------------
  Fetal plasma arterial insulin, ng/mL            0.26 ± 0.03    0.92 ± 0.20\*\*   0.92 ± 0.10\*\*
  Fetal plasma arterial carbohydrates, μmol/L                                     
   Glucose                                        1,338 ± 96        998 ± 76          1,201 ± 79
   Mannose                                        33.9 ± 2.1     18.9 ± 2.4\*\*     16.8 ± 2.1\*\*
   Inositol                                      838.2 ± 165.2    703.1 ± 144.3      673.3 ± 85.0
   Sorbitol                                      163.4 ± 62.7     134.2 ± 76.1       82.5 ± 27.1
   Fructose                                       5,751 ± 884    3,214 ± 673\*\*   2,658 ± 538\*\*
   Erythritol                                    402.1 ± 38.2    356.5 ± 32.2\*    330.3 ± 32.0\*\*
   Arabinol                                      193.9 ± 24.1     176.5 ± 28.4       178.3 ± 23.8
   Ribitol                                       153.1 ± 21.4     148.9 ± 22.0       133.9 ± 17.1
   Mannitol                                       69.4 ± 5.8       64.5 ± 10.0        60.1 ± 8.8

Values are means ± SEM. \*, \*\* refer to significant differences from d0; *P* \< 0.05, 0.01, respectively, by ANOVA. n = 6.

Discussion
==========

Non glucose carbohydrates are important for normal fetal development \[[@B1]-[@B4]\]. Pathological conditions in pregnancy that adversely affect glucose delivery to the fetus could affect the delivery of non glucose carbohydrates. Therefore, the primary goal of the current study was to determine how a maternal insulin infusion with an associated reduction in glucose supply to the fetus affected the plasma concentrations of these metabolites in both the maternal and fetal circulations. We found that a maternal insulin infusion which reduced glucose supply to the fetus of both short (2-wk) and long (8-wk) durations resulted in decreased maternal and fetal mannose concentrations along with decreased fetal concentrations of sorbitol and fructose. As in human pregnancies, fetal and maternal arterial plasma mannose concentrations were highly correlated, suggesting that maternal mannose concentration determines fetal mannose concentrations. However, a physiological increase in fetal insulin after prolonged fetal hypoglycemia further reduced circulating fetal mannose concentrations, indicating that insulin also plays a key role in regulating mannose concentrations. Finally, we found that neither maternal nor fetal arterial plasma inositol concentrations changed with exogenous insulin infusions.

The most striking findings in this study relate to the regulation of fetal mannose concentrations. There has been emerging evidence in both normal human and sheep pregnancies that the fetus is dependent on placental delivery of mannose \[[@B9],[@B10],[@B32]\]. In fact, in human pregnancies, it appears that over 95% of fetal circulating mannose is derived from transplacental transfer from the mother \[[@B10]\]. Our findings also support transplacental transfer of mannose from the mother as the dominant source of circulating fetal mannose, as we found that maternal and fetal plasma arterial mannose concentrations were highly correlated when an experimental maternal insulin infusion decreased maternal mannose concentrations. Furthermore, we found a significant decrease in the maternal to fetal mannose concentration difference in 8-wk HG sheep. This finding suggests that decreased fetal mannose concentrations were due to decreased maternal mannose concentrations rather than a decrease in placental transport capacity. In fact, when fetal and maternal mannose concentrations were measured in a sheep model of chronic placental insufficiency there was a significant increase in the maternal to fetal mannose concentration gradient, indicating that placental insufficiency has the potential to disrupt maternal to fetal mannose delivery \[[@B22]\].

Our results also demonstrate a key role for insulin in the regulation of both maternal and fetal plasma mannose concentrations. We report for the first time that long term (8-wk) maternal insulin infusion during pregnancy results in a 50% reduction in maternal mannose concentrations. As these maternal ewes were also chronically hypoglycemic, we cannot determine whether chronic hypoglycemia or chronic hyperinsulinemia was directly responsible for reductions in mannose concentrations. However, previous work in rodents and adults has shown that insulin is independently involved in lowering plasma mannose by suppressing hepatic glycogen breakdown and mannose efflux from the liver \[[@B16],[@B18]\]. In healthy adults, oral glucose administration increased both glucose and insulin concentrations yet mannose concentrations were still decreased, arguing for insulin stimulated mannose disposal independent of glucose \[[@B17],[@B19]\].

From the present study, however, we were able to gain some insight into the independent effects of glucose and insulin on circulating mannose in the fetus. When a direct fetal insulin infusion restored physiological insulin concentrations in 8-wk HG+I fetuses and fetal glucose concentrations were maintained, fetal mannose concentrations were further reduced by 50%. This argues for insulin mediated reductions in fetal plasma mannose to extremely low concentrations (\~8 μmol/L) independent of concurrent hypoglycemia. To further determine the independent effects of glucose and insulin on fetal mannose, we infused insulin with a concurrent dextrose infusion to maintain glucose concentrations in a separate group of normal late gestation fetuses. This fetal hyperinsulinemic-euglycemic clamp also resulted in decreased mannose concentrations, confirming a role for insulin in the regulation of fetal mannose independent of glucose concentrations.

We also showed decreased fetal arterial plasma sorbitol and fructose concentrations in 8-wk HG fetuses. Contrary to our hypothesis, fetal plasma inositol concentrations were maintained during restricted fetal glucose supply. Maternal glucose has several potential fates once it enters the placenta. It can be directly transferred to the fetus or oxidized for fuel production \[[@B10],[@B33]\]. Additionally, the placenta can convert glucose to inositol or sorbitol \[[@B9],[@B22],[@B32]\]. Glucose is converted to inositol by glucose-6-phosphate:1-phosphate cyclase and to sorbitol by aldose reductase \[[@B34]-[@B36]\]. The balance between these two pathways is regulated by NADPH derived from the placental uptake of glutamate from the fetus \[[@B37]-[@B40]\]. Although we did not directly measure placental glutamate uptake in this study, fetal arterial plasma glutamate concentrations are reduced by 50% in HG fetuses, which might lead to a reduction in placental NADPH availability \[[@B41]\]. This would, in turn, limit placental production of sorbitol and preserve or increase the production of inositol. This also is consistent with our findings of decreased fetal plasma fructose and decreased hepatic sorbitol and fructose, as the major fate for fetal sorbitol in the sheep is conversion to fructose in the liver by sorbitol dehydrogenase.

Interestingly, fetal fructose concentrations also are decreased by fetal insulin infusion independent of glucose. Relationships between fructose and insulin have been previously reported, such that pancreatectomized fetal sheep have increased fructose concentrations \[[@B42]\], and fructose infusion into the sheep fetus can stimulate insulin secretion \[[@B43]\]. The role of fructose in human fetal and neonatal development remains to be determined, though postulated roles include alternative pathways in glucose metabolism, redox balance, and lipid synthesis \[[@B6],[@B44]\].

The results of our study are limited only to changes in maternal and fetal arterial plasma concentrations of carbohydrates and polyols, thus conclusions cannot be made regarding their uptake and utilization rates by the fetus. However, the results are consistent with previous studies in human fetuses showing placental transport of maternal mannose, fetal production of inositol, and placental export to the fetus of sorbitol \[[@B9],[@B10]\]. Future studies are warranted to determine the effects of fetal glucose and insulin on uptake, production, and utilization rates of these carbohydrates, thus providing a more in depth understanding of their metabolism in the pregnant mother and fetus.

Conclusions
===========

In summary, the results of this study show that a chronic and constant maternal insulin infusion suppresses both maternal and fetal mannose concentrations by approximately 50%. Additionally, insulin can suppress fetal mannose and fructose concentrations independent of glucose availability. The functional implications of this degree of fetal hypomannosemia are unclear, but a recent report demonstrating embryonic lethality in mice with a hypomorphic phosphomannomutase 2 gene defect shows the critical role of mannose in normal fetal development \[[@B4]\]. Our results also show a significant reduction in fetal sorbitol concentrations, likely due to decreased placental sorbitol production and transfer to the fetus following increased shuttling of placental glucose into inositol production. Taken together, our findings demonstrate the potential for other carbohydrates, in addition to glucose, to be adversely affected by alterations in maternal and/or fetal insulin concentrations and glucose supply. Given the important role that many of these non glucose carbohydrates have in fetal development, future research on pathological conditions in pregnancy should include further investigation into carbohydrate metabolism beyond glucose, especially when conditions of fetal hyperinsulinemia are considered.
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